Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29069970 | 0.88 | JAK2 (0.48) | JAK2JAK1GPR119AGTR2MEN1 | |
| SCHEMBL29069971 | 0.88 | JAK2 (0.48) | JAK2JAK1GPR119AGTR2MEN1 | |
| SCHEMBL20920379 | 0.88 | JAK2 (0.48) | JAK2JAK1GPR119AGTR2MEN1 | |
| SCHEMBL25487553 | 0.85 | AGTR2 (0.48) | AGTR2MEN1KMT2ATACR1 | |
| SCHEMBL25487683 | 0.81 | GPR119 (0.41) | JAK2JAK1NPSR1MAPTGRM5 | |
| SCHEMBL31240064 | 0.78 | JAK2 (0.61) | JAK2JAK1GPR119AGTR2KMT2A | |
| SCHEMBL21896341 | 0.77 | JAK2 (0.43) | JAK2JAK1GPR119AGTR2HSD11B1 | |
| SCHEMBL23813579 | 0.76 | JAK2 (0.59) | JAK2JAK1GPR119AGTR2KMT2A | |
| SCHEMBL23291066 | 0.76 | JAK2 (0.59) | JAK2JAK1GPR119AGTR2KMT2A | |
| SCHEMBL24090884 | 0.76 | JAK2 (0.59) | JAK2JAK1GPR119AGTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | JAK2 3594/4885JAK1 3433/4885NPSR1 3931/4885 |
| US-11655217-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | JAK2 3385/4885JAK1 3064/4885NPSR1 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.